Immunological profile and dyslipidemia in Egyptian Systemic Lupus Erythematosus patients

Immunological profile and dyslipidemia in Egyptian Systemic Lupus Erythematosus patients

To study the relation of the immune profile to dyslipidemia in a cohort of Egyptian Systemic Lupus Erythematosus (SLE) patients. This study included 221 SLE patients with a disease duration >6months at study entry. Disease activity was assessed using the SLE Disease Activity Index (SLEDAI) and se...

Full description

Saved in:
Bibliographic Details
Published in:Egyptian rheumatologist Vol. 39; no. 2; pp. 89 - 92
Main Authors: Gamal, Sherif M., Fawzy, Samar M., Abdo, Marwa, Elgengehy, Fatema T., Ghoniem, Shada, Alkemry, Alkhateeb
Format: Journal Article
Language:English
Published: Elsevier B.V 01-04-2017
Subjects:
Anti-Ro
Dyslipidemia
Immune profile
SLE
SLEDAI
SLEDAI
Anti-Ro
SLE
Dyslipidemia
Immune profile
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To study the relation of the immune profile to dyslipidemia in a cohort of Egyptian Systemic Lupus Erythematosus (SLE) patients. This study included 221 SLE patients with a disease duration >6months at study entry. Disease activity was assessed using the SLE Disease Activity Index (SLEDAI) and severity using the Systemic Lupus International Collaborating Clinics/Damage Index (SLICC/DI). Patients were investigated for the anti-nuclear antibody (ANA), anti-double stranded deoxy-ribonucleic acid (anti-dsDNA), anti-cardiolipin (ACL) antibodies (IgG and IgM), anti Ro (SSA) and anti La (SSB). Dyslipidemia was considered if the high density lipoproteins (HDL), low density lipoproteins (LDL), total cholesterol (TC) or triglycerides (TG) were abnormal. The mean age of the patients was 28.8±7.8years and the median disease duration was 5years. The clinical manifestations of the patients were pleurisy (52.9%), pericarditis (24.9%), nephritis (68.3%), CNS lupus (23.1%), vasculitis (14.9%) and musculoskeletal manifestations (57.9%). All patients were on corticosteroids (median dose 35mg/day; range 5–80mg/day), while 92 (43.4%) of them received cyclophosphamide during their disease course. The mean SLEDAI was 12.1±7.4 and SLICC/DI was 1.4±1.6. Patients with positive anti-Ro (n=44; 19.9%) showed statistically significant lower level of HDL (p=0.01). Positive anti-Ro may be associated with increased incidence of low HDL in lupus patients which in turn may increase the incidence of cardiovascular accidents.
ISSN:1110-1164
2090-2433
DOI:10.1016/j.ejr.2016.05.007